Cat. No.: 218 611
Amount: 100 µg
Price:
$415.00
|
|
|
| Cat. No. 218 611 |
100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications | |
| Clone | 70D7 |
| Subtype | IgG3 (κ light chain) |
| Immunogen | Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067) |
| Reactivity |
Reacts with: human (P05067), rat (P08592), mouse (P12023). Other species not tested yet. |
| Specificity | Recognizes specific oligomeric structures formed preferentially by Abeta-pE3. |
| Remarks |
WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested. |
| Data sheet | 218_611.pdf |
|
|
Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.